Ann: Recce Pharmaceuticals - Business Update, page-15

"not entirely clear about what all the limits of practical use are in all cases".

Well, that is the understatement of the year. We're starting to get a very good picture. Over 8 or 9 years, here are all the uses that RCE have announced and either been abandoned or not updated:

- Blood sepsis (can't get the stuff into the blood fast enough?)
- COVID (hamsters died?)
- Influenza (abandoned?)
- Burns (trial abandoned - couldn't recruit patients)
- H. pylori (abandoned?)
- Sinus (abandoned?)
- Mycobacterium (abandoned?)

I'm probably forgetting many more.

A UTI phase 1 is active, but the fact that they need to keep going to higher and faster infusions is a pretty big clue about what might be going on.
The DFI trial is interesting but as always with RCE, the truth is so obscured with misdirection and sloppiness that you can't really assume anything.